Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

References

• American Diabetes Assocition. Standards of medical care in diabetes – 2018. Diabetes Care. 2018;41:S1–S159. doi:10.2337/dc18-073329222369
   PubMedGoogle Scholar
• International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: Interntional Diabetes Federtion; 2017.
   Google Scholar
• Bae JC. Trends of diabetes epidemic in Korea. Diabetes Metab J. 2018;42(5):377–379. doi:10.4093/dmj.2018.019430362303
   PubMed Web of Science ®Google Scholar
• Noh J, Han KD, Ko SH, Ko KS, Park CY. Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep. 2017;7:46656.28425463
   PubMed Web of Science ®Google Scholar
• Barlow SE, Expert C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–S192.18055651
   PubMed Web of Science ®Google Scholar
• Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3(1):60–63.15671192
   PubMed Web of Science ®Google Scholar
• Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics. 2005;116(2):473–480.16061606
   PubMed Web of Science ®Google Scholar
• Papatheodorou K, Papanas N, Banach M, Papazoglou D, Edmonds M. Complications of diabetes 2016. J Diabetes Res. 2016;2016:6989453.27822482
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188.23303908
   PubMed Web of Science ®Google Scholar
• Wojciechowska J, Krajewski W, Bolanowski M, Krecicki T, Zatonski T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–275. doi:10.1055/s-0042-10091027219686
   PubMed Web of Science ®Google Scholar
• Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104(1):9–14. doi:10.1111/cas.1204323066889
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 2011;1243:54–68. doi:10.1111/j.1749-6632.2011.06285.x22211893
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–748. doi:10.1152/physrev.00030.201426084689
   PubMed Web of Science ®Google Scholar
• Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–1123. doi:10.1677/ERC-09-008719620249
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29(2):1314–1327. doi:10.1007/s12032-011-9846-721301998
   PubMed Web of Science ®Google Scholar
• Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: an existing drug for cancer prevention and therapy. Oncol Lett. 2018;15(1):683–690. doi:10.3892/ol.2017.741229422962
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):57.25333032
   PubMedGoogle Scholar
• Noh Y, Lee S, Shin S. Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients. Ther Clin Risk Manag. 2018;14:1563–1571. doi:10.2147/TCRM.S16996430233191
   PubMed Web of Science ®Google Scholar
• Noh Y, Kang DR, Kim DJ, Lee KJ, Lee S, Shin S. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. Pharmacoepidemiol Drug Saf. 2017;26(11):1338–1346. doi:10.1002/pds.426228771933
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi:10.1007/s00125-018-4729-530288571
   PubMed Web of Science ®Google Scholar
• Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):34–46. doi:10.1111/dom.2018.20.issue-S1
   Google Scholar
• Scavone C, Sportiello L, Rafaniello C, et al. Incretin-based therapies and cancer risk: a reivew of recent literture safety data. Daibetes Manag. 2016;6:014–022.
   Google Scholar
• Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obesity Metab. 2016;18:333–347. doi:10.1111/dom.12610
   PubMed Web of Science ®Google Scholar
• Shin S, Kim H. The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. Ther Clin Risk Manag. 2016;12:435–444. doi:10.2147/TCRM.S10528527042085
   PubMed Web of Science ®Google Scholar
• Wang H, Liu X, Long M, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med. 2016;8(334):334ra351. doi:10.1126/scitranslmed.aaf0746
   Web of Science ®Google Scholar
• Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014;38(5):330–336. doi:10.4093/dmj.2014.38.5.33025349819
   PubMedGoogle Scholar
• Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des. 2007;13(7):671–686.17346183
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451–1461. doi:10.1158/1940-6207.CAPR-10-015720947488
   PubMed Web of Science ®Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094. doi:10.1007/s40265-015-0416-826059289
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. doi:10.1007/s00125-017-4342-z28776086
   PubMed Web of Science ®Google Scholar
• Kinzig KP, Honors MA, Hargrave SL. Insulin sensitivity and glucose tolerance are altered by maintenance on a ketogenic diet. Endocrinology. 2010;151(7):3105–3114. doi:10.1210/en.2010-017520427477
   PubMed Web of Science ®Google Scholar
• Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012:928127. doi:10.1155/2012/92812722701483
   PubMedGoogle Scholar
• Karnevi E, Said K, Andersson R, Rosendahl A. Metformin-mediated growth inhibition invovles suppression of the IGF_I receptor signaling pathway in human pancreatic cancer cells. BMC Cancer. 2013;13:235–245. doi:10.1186/1471-2407-13-23523663483
   PubMed Web of Science ®Google Scholar
• Tadakawa M, Takeda T, Li B, Tsuiji K, Yaegashi N. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1alpha signaling pathway in ELT-3 cells. Mol Cell Endocrinol. 2015;399:1–8. doi:10.1016/j.mce.2014.08.01225179820
   PubMed Web of Science ®Google Scholar
• Pathak R, Bridgeman M. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. PT. 2010;35:509–513.
   PubMedGoogle Scholar
• Feng X, Cai A, Dong K, et al. Assessing pancreatic cancer risk associated with dipeptidyl peptidase 4 inhibitors: data mining of FDA Adverse Event Reporting System (FAERS). J Pharmacovigil. 2013;01(03):110.
   Google Scholar
• Overbeek JA, Bakker M, van der Heijden A, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004. doi:10.1002/dmrr.300429573125
   PubMed Web of Science ®Google Scholar
• Rathmann W, Kostev K. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. J Diabetes Complications. 2017;31(4):687–692. doi:10.1016/j.jdiacomp.2017.01.01228169131
   PubMed Web of Science ®Google Scholar
• Zhao M, Chen J, Yuan Y, et al. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep. 2017;7(1):8273.28811622
   PubMedGoogle Scholar
• Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782.29335646
   PubMed Web of Science ®Google Scholar
• Noh Y, Jeon SM, Shin S. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. Int J Cancer. 2019;144(7):1530–1539.30229901
   PubMed Web of Science ®Google Scholar
• Novosyadlyy R, Lann DE, Vijayakumar A, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 2010;70(2):741–751.20068149
   PubMed Web of Science ®Google Scholar
• Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011;8:75.22029671
   PubMed Web of Science ®Google Scholar